Skip to main content
All
Stories
Press Releases
Documents
Events
Updates
Other
Press shift tab to select search category
Loading...
Newsroom
< Back
Newsroom
Press Releases
Media Updates
Media Resources
Media Contacts
Subscribe
Investors
< Back
Investors
Investors
Financial Results
Annual Reports & Regulated Information
Investor Events & Financial Calendar
Shareholder Information
Subscribe
Ratings & Bonds
Careers
< Back
Careers
Careers
Working at Ipsen
Culture
Job Search
Contacts
< Back
Contacts
Contacts
Our Locations
Report Side Effects
Subscribe
All
Stories
Press Releases
Documents
Events
Updates
Other
Press shift tab to select search category
X
Loading...
English EN
Français FR
EN
English
EN
Français
FR
Global
< Back
Global
EN
FR
Annual Report
EN
FR
Americas
Asia Pacific
Europe
Middle East & Africa
United States
Brazil
Canada
Mexico
Australia
China
Singapore
South Korea
Japan
Belgium
Ukraine
UK
Germany
France
Nordics
Greece
Italy
Netherlands
Spain
Poland
Russia
Czech Republic
Switzerland
Austria
UAE & Gulf
Saudi Arabia
Home
Company
< Back
Company
Company
Leadership
History
Fondation Ipsen
Expertise
< Back
Expertise
Oncology
Rare Disease
Neuroscience
Medicines
Science
< Back
Science
Science
< Back
Science
Oncology
Rare Disease
Neuroscience
Profiles
Partnering
< Back
Partnering
Therapeutic focus
Meet the team
Clinical Trials
< Back
Clinical Trials
Lay Summaries
Find Clinical Trials
Pipeline
Sustainability
< Back
Sustainability
Sustainability
Environment
Patients
People
Governance
Our Standards
Patients
< Back
Patients
Patients
Together for Oncology
Together for Rare Disease
Together for Neuroscience
Collaborate with us
Stories
Post navigation
Previous
Next
Onivyde
®
(irinotecan liposome injection)
Onivyde
®
(irinotecan liposome injection)
-
28 April 2023
-
0 mins read
Post navigation
Previous
Next
X
You are now leaving the Ipsen group global website. To continue, please click on
Continue
?